SCHEMBL21323246

SCHEMBL21323246

O=C(CCc1ccc(-c2cccnc2)cc1)N1CC2CN(C(=O)c3ccc4[nH]nnc4c3)CC2C1

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ MKNK1 Q9BUB5 1/20 0.42
▸ MKNK2 Q9HBH9 1/20 0.42
▸ ABL1 P00519 3/20 0.41
▸ BCR P11274 3/20 0.41
▸ GHSR Q92847 1/20 0.41
▸ HTR2B P41595 1/20 0.40
▸ CHRNB2 P17787 1/20 0.39
▸ CHRNB4 P30926 1/20 0.39
▸ CHRNA3 P32297 1/20 0.39
▸ CHRNA7 P36544 1/20 0.39
▸ CHRNA4 P43681 1/20 0.39
▸ HPGD P15428 2/20 0.37
▸ PRCP P42785 1/20 0.37
▸ NAAA Q02083 1/20 0.36
▸ GRIN2B Q13224 1/20 0.36
▸ GSK3B P49841 1/20 0.36
▸ ALDH1A1 P00352 1/20 0.36
▸ SLC6A7 Q99884 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16963390 1.00 MKNK1 (0.42) MKNK1MKNK2ABL1BCRGHSR
SCHEMBL16962981 0.91 NAAA (0.45) GHSRHTR2BNAAASLC6A7
SCHEMBL18540872 0.91 NAAA (0.45) GHSRHTR2BNAAASLC6A7
SCHEMBL21323107 0.90 LSS (0.39) GHSRCHRNB2CHRNB4CHRNA3CHRNA7
SCHEMBL16963841 0.90 LSS (0.39) GHSRCHRNB2CHRNB4CHRNA3CHRNA7
SCHEMBL20101594 0.89 MKNK1 (0.52) MKNK1MKNK2ABL1BCRGHSR
SCHEMBL16963393 0.86 HTR2B (0.37) MKNK1MKNK2ABL1BCRGHSR
SCHEMBL16963777 0.86 KDM5C (0.43) HPGD
SCHEMBL21322925 0.86 KDM5C (0.43) HPGD
SCHEMBL21322941 0.85 KDM5C (0.41) ABL1BCRGHSRHTR2BHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2900669-B1 HEXAHYDROPYRROLO[3,4-C]PYRROLE DERIVATIVES AND RELATED COMPOUNDS AS AUTOTAXIN (ATX) INHIBITORS AND AS INHIBITORS OF THE LYSOPHOSPHATIDIC ACID (LPA) PRODUCTION FOR TREATING E.G. RENAL DISEASES HOFFMANN LA ROCHE (CH) 2019-09-04 — — EP disclosed
Send feedback